Thr724
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Thr724 - APP iso8 (human)

Site Information
VEVDAAVtPEERHLS   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: APP iso2 (mouse): T668, APP (mouse): T743, APP iso4 (human): T668, APP iso2 (rat): T668, APP (rat): T743, APP (human): T743, APP iso10 (human): (T612)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448523

In vivo Characterization
Methods used to characterize site in vivo: mutation of modification site (2), phospho-antibody (1), western blotting (1)
Disease tissue studied: brain cancer (2), glioblastoma (2), glioma (2), sporadic inclusion-body myositis (1)
Relevant cell line - cell type - tissue: 'muscle, skeletal' (1), U87MG (glial) (2)

Controlled by
Treatments: epoxomicin (1), lithium (1), thapsigargin (1), tunicamycin (1)



References

1

Terracciano C, Nogalska A, Engel WK, Askanas V (2010) In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 112, 389-96
19878439   Curated Info

2

Jacobsen JS, et al. (1994) The release of Alzheimer's disease beta amyloid peptide is reduced by phorbol treatment. J Biol Chem 269, 8376-82
8132561   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.